Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Psoriasis in Europe

被引：0
|
作者：
Jin, Ran [1 ]
Wrest, Eleanor [2 ]
Haughton, James [2 ]
Piercy, James [2 ]
Meadows, Rachel [2 ]
Radziszewski, Waldemar [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
[2] Adelphi Real World, Bollington, England
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB216 / AB216
页数：1
相关论文
共 50 条
  • [31] Real-World Patterns in Treatment Switching to Biosimilar Adalimumab in the United States
    Rodriguez, Patricia J.
    Cartwright, Brianna M.
    Gratzl, Samuel
    Do, Duy
    Baker, Charlotte
    Stucky, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 157 - 158
  • [32] Resource utilization and costs associated with adalimumab or etanercept for moderate to severe psoriasis in a real-world setting
    Papp, Kim
    Guerin, Annie
    Gupta, Shiraz
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB159 - AB159
  • [33] Patient perspectives from a real-world adalimumab biosimilar switching program
    Choon, X. Y.
    Moore, A.
    Sharma, E.
    Anderson, S.
    Gecse, K.
    Mawdsley, J.
    Ray, S.
    Dart, R.
    Irving, P.
    Samaan, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1761 - i1761
  • [34] Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada
    Cheung, Winson Y.
    Samimi, Setareh
    Ma, Kim
    Knight, Gregory John
    Kassam, Shaqil
    Colwell, Bruce
    Beaudoin, Annie
    Vincent, Mark David
    Trinkaus, Mateya
    Filion, Alain
    Marquis, Katerine
    Karachiwala, Hatim
    Asmis, Timothy
    Sideris, Lucas
    Wani, Rajvi J.
    Ngan, Elaine
    Inam, Naila
    Du, Yinhao
    Nunez, Leyla
    Eberg, Maria
    Alemayehu, Mistre
    Meyer, Pierre-Francois
    Mancini, Johanna
    Morris, Carlye Cirone
    CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 46 - 57.e4
  • [35] Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept
    Ribaldone, Davide Giuseppe
    Vernero, Marta
    Astegiano, Marco
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (02) : 155 - 155
  • [36] Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
    Barberio, B.
    Zingone, F.
    Ferronato, A.
    Buda, A.
    Melatti, P.
    Gubbiotti, A.
    Massimi, D.
    Casadei, C.
    Cingolani, L.
    Savarino, E. V.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S397 - S397
  • [37] Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
    Papp, Kim
    Bachelez, Herve
    Costanzo, Antonio
    Foley, Peter
    Gooderham, Melinda
    Kaur, Primal
    Narbutt, Joanna
    Philipp, Sandra
    Spelman, Lynda
    Weglowska, Jolanta
    Zhang, Nan
    Strober, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : 1093 - 1102
  • [38] Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn's disease
    Halder, S.
    Khan, W.
    Wang, X.
    Kuhns, S.
    Sweet, H.
    Reinisch, W.
    McBride, H.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S121 - S121
  • [39] Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Malatestinic, William N.
    Lin, Chen-Yen
    Lew, Carolyn R.
    Zimmerman, Nicole M.
    Goldblum, Orin M.
    Zhu, Baojin
    Murage, Mwangi J.
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 517 - 527
  • [40] OUTCOMES OF BIOSIMILAR ADALIMUMAB SWITCHBACKS/REVERSE SWITCHING IN IBD: REAL-WORLD EXPERIENCE
    Norredinvand, Hesam Ahmadi
    Bishop, Sophia
    Patel, Janki
    Sivanesan, Naveenaa
    Fong, Steven
    GUT, 2021, 70 : A94 - A94
12345